About Daewoong

Holding Company

  • Daewoong
    Resource management and management support for affiliated companies
    Go to homepage

Daewoong Affiliates

  • Daewoong Pharmaceutical
    Manufacture and sales of finished dose
    Go to homepage
  • Daewoong Bio
    Manufacture and sales of API
    Go to homepage
  • Daewoong Life Science
    Production and sales of health food and life products
    Go to homepage
  • DMD Daewoong Management Development Institute
    Corporate personnel training business
    Go to homepage
  • idsTrust
    Computer, peripheral devices and software development and sales
    Go to homepage
  • Daewoong ENG
    Facility management services and machine production
    Go to homepage
  • Pharm Pack
    Pharmaceutical product packaging professionals
  • Daewoong Development
    Real estate leasing
  • Sanwoong Development
    Facility management services
  • Daewoong Therapeutics
    R&D on first-in-class DR/DDS-based new drugs
    Go to homepage

Daewoong Pharmaceutical Affiliates

  • Hanall Biopharma
    Pharmaceutical product R&D
    Go to homepage
  • MD Well
    Medicine and nutrition company, production and sales of nutritious meals
    Go to homepage
  • Healience Seonmaeul
    New conceptual lifestyle improvement program, and the nation’s first wellness center
    Go to homepage
  • Affyxell Therapeutics
    R&D on pharmaceutical drugs and medicine
    Go to homepage
  • iN Therapeutics
    R&D on pharmaceutical drugs and medicine
affyxell logo
Affyxell Therapeutics
R&D on pharmaceutical drugs and medicine
Establishment History
CEO:
Seng Ho Jeon & Jong Sang Ryu
Date of establishment:
February 06, 2020
Headquater:
Kimhae, Korea
(Kimhae Biomedical Center)
R&D center:
Yong In, Korea (Gwanggyo)
Vision
A right of all mankind is a life that is
healthy, joyful, and gratifying,
free from suffering of illnesses.
Mission
AffyXell provides a new class of
affordable cellular therapeutics that
help patients recover from intractable
disease and regain their health.

Limit 1.

Limitations of Current Stem
Cell Therapy

  • icon

    Donor variance

  • icon

    High cost
    Low efficacy

  • icon

    Need for
    specific MoA

Limit 2.

Limitations of Current Non-IgG
Scaffold

  • icon

    Relatively short
    Half-life compared to
    Antibody drugs

  • icon

    Low efficacy
    Compared to
    Competitive
    treatments

  • icon

    Lack of feasible
    New substances

Overcoming Barriers

Next Generation Cell Therapy
(AFX Platform)

AFX platform :
Affimer-encoded Mesenchymal Stem Cells

Overcoming donor variance by using
pluripotent stem cell-derived MSC

Improved productivity
in cell therapy by using pluripotent
stem cell-derived MSC

Securing specific treatment
mechanism through Affimer gene
introduction

Synergy through
platform convergence
In-body factory :
overcoming a short half-life of
Affimer
Superior efficacy expected
compared to
competitor treatments

* Pluripotent stem cell-derived Mesenchymal Stem Cell